Pandemic Perspectives: Safety Monitoring Boost For COVID Vaccines Creating ‘A New Normal’ For Pharmacovigilance
Executive Summary
Pink Sheet infographic puts together the many new and existing safety systems being used to track and evaluate COVID-19 vaccine adverse events. There are early signs the vaccination effort has led to heightened public attention on medication safety that may be here to stay.
You may also be interested in...
FDA Advisors Give Entasis Antibiotic Unanimous Thumbs Up, But Call For Strong Postmarket Surveillance
High unmet need and a potentially more favorable safety profile than current options got sulbactam-durlobactam a favorable advisory panel.
Califf: FDA Vaccine Safety Oversight Would Be Enhanced By Federal Public Health Data Authority
US FDA continues to push for new federal funding and authorities to improve vaccine safety surveillance.
PDUFA VII Will Fund Pregnancy Postmarket Safety Update, Sentinel Upgrades, REMS Standardization
US FDA will incorporate performance goals for reviewing REMS methodological approaches and study protocols as part of PDUFA reauthorization.